InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,581.17
(
0.15%
)
US TECH 100
19,882.40
(
-0.06%
)
Dow Jones
39,368.31
(
0.06%
)
Brent Oil
84.66
(
-0.88%
)
Bitcoin
57,540.25
(
1.47%
)
Post# of 252528
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: DewDiligence post# 153062

Wednesday, 02/20/2013 10:26:51 AM

Wednesday, February 20, 2013 10:26:51 AM

Post# of 252528
Teva, Gilead settle US patent dispute over generic version of Viread

Teva and Gilead Sciences agreed to settle a US patent dispute over the HIV and chronic hepatitis B therapy Viread (tenofovir), avoiding a trial that was scheduled to start Wednesday, Gilead reported. Under the deal, Teva will be allowed to launch a generic version of Viread on December 15, 2017.



http://www.firstwordpharma.com/node/1059686
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up